$0.00 EPS Expected for Zedge (ZDGE), Impax Laboratories (IPXL) Shorts Up By 8.15%

May 30, 2017 - By Darrin Black

Analysts expect Zedge Inc (NYSEMKT:ZDGE) to report $0.00 EPS on June, 8. The stock decreased 1.00% or $0.03 on May 26, reaching $2.97. About shares traded. Zedge Inc (NYSEMKT:ZDGE) has 0.00% since May 30, 2016 and is . It has underperformed by 16.70% the S&P500.

Impax Laboratories Incorporated (NASDAQ:IPXL) had an increase of 8.15% in short interest. IPXL’s SI was 8.65M shares in May as released by FINRA. Its up 8.15% from 8.00 million shares previously. With 1.67 million avg volume, 5 days are for Impax Laboratories Incorporated (NASDAQ:IPXL)’s short sellers to cover IPXL’s short positions. The SI to Impax Laboratories Incorporated’s float is 13.06%. The stock decreased 3.79% or $0.6 on May 26, reaching $15.25. About shares traded. Impax Laboratories Inc (NASDAQ:IPXL) has declined 49.01% since May 30, 2016 and is downtrending. It has underperformed by 65.71% the S&P500.

Zedge, Inc. is a provider of content distribution platforms, centered on self-expression, enabling both creators looking to promote their content and clients utilizing such content to express their identity, feelings, tastes and interests. The company has market cap of $28.36 million. The Company’s platform enables clients to personalize their mobile devices with free, ringtones, wallpapers, home screen application icons and notification sounds. It currently has negative earnings. The users primarily access the Company’s content through its smartphone application, called Zedge.

Investors sentiment decreased to 1.18 in Q4 2016. Its down 0.25, from 1.43 in 2016Q3. It is negative, as 31 investors sold Impax Laboratories Inc shares while 51 reduced holdings. 36 funds opened positions while 61 raised stakes. 57.71 million shares or 5.44% less from 61.03 million shares in 2016Q3 were reported. Gsa Prtn Llp invested in 0.02% or 20,294 shares. Wells Fargo & Comm Mn owns 61,358 shares for 0% of their portfolio. Solaris Asset Mgmt Lc accumulated 925 shares. Millennium Mngmt Ltd Liability holds 0.01% or 200,015 shares. Jpmorgan Chase & holds 475,981 shares. Aperio Limited Liability Com accumulated 17,570 shares or 0% of the stock. State Of Alaska Department Of Revenue has invested 0.01% of its portfolio in Impax Laboratories Inc (NASDAQ:IPXL). Paloma Partners Mgmt Company, Connecticut-based fund reported 54,574 shares. Los Angeles Capital Mgmt And Equity Research holds 0% or 10,835 shares in its portfolio. Parkside Commercial Bank & accumulated 0% or 51 shares. Kcg Holdg Incorporated reported 32,620 shares. Citadel Advsrs Limited Liability reported 209,706 shares or 0% of all its holdings. Lsv Asset Mgmt has 24,100 shares for 0% of their portfolio. Everpoint Asset Mgmt Ltd Liability Corp holds 800,000 shares. Ny State Common Retirement Fund owns 79,500 shares.

Since May 12, 2017, it had 0 buys, and 2 sales for $26,096 activity. $11,977 worth of Impax Laboratories Inc (NASDAQ:IPXL) shares were sold by NESTOR MICHAEL.

Impax Laboratories, Inc. is a specialty pharmaceutical company. The company has market cap of $1.08 billion. The Firm is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products , in addition to the development and marketing of branded products. It currently has negative earnings. The Company’s divisions include Impax Generics and Impax Specialty Pharma.

Among 14 analysts covering Impax Laboratories Inc. (NASDAQ:IPXL), 3 have Buy rating, 2 Sell and 9 Hold. Therefore 21% are positive. Impax Laboratories Inc. had 20 analyst reports since July 21, 2015 according to SRatingsIntel. Deutsche Bank maintained the stock with “Hold” rating in Wednesday, August 10 report. The company was maintained on Thursday, November 10 by RBC Capital Markets. The rating was initiated by Susquehanna on Tuesday, July 21 with “Positive”. The stock of Impax Laboratories Inc (NASDAQ:IPXL) earned “Neutral” rating by Goldman Sachs on Tuesday, September 27. Nomura initiated Impax Laboratories Inc (NASDAQ:IPXL) on Tuesday, September 29 with “Neutral” rating. The firm has “Underperform” rating given on Monday, November 7 by Bank of America. Goldman Sachs initiated the stock with “Sell” rating in Monday, June 6 report. The firm earned “Market Perform” rating on Tuesday, April 19 by Northland Capital. JP Morgan initiated Impax Laboratories Inc (NASDAQ:IPXL) rating on Wednesday, January 6. JP Morgan has “Neutral” rating and $47 target. Janney Capital initiated it with “Neutral” rating and $15 target in Wednesday, December 28 report.